INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY

人类妊娠期对 HCV 的先天性和适应性免疫

基本信息

  • 批准号:
    8654226
  • 负责人:
  • 金额:
    $ 33.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-02-07 至 2019-01-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Hepatitis C virus (HCV) is the most common blood-borne infection in the United States, with an overall prevalence of ~2%, and an estimated 200 million chronically infected people worldwide. A substantial body of evidence, including work from our laboratory, supports the concept that early events in the coordination and nature of multi-cellular immune responses are critical in determining whether the virus is cleared or whether persistence is established. However, despite the fact that approximately 40,000 pregnancies occur each year in HCV-infected women, little is known about the immunopathogenesis or correlates of protective immunity in this setting, in part because pregnant women with chronic HCV have hitherto been excluded from studies of immunity. For the first time, we present evidence that trophoblasts, specialized cells of the placenta that play important roles in embryo implantation and interaction with decidualized maternal uterus, can take up HCV proteins as well as respond to a viral product of hepatitis C (known as a pathogen-associated molecular pattern or PAMP) by producing high levels of Type III IFNs. These intriguing results corroborate the recent studies demonstrating genetic associations with single nucleotide polymorphisms that encode interferon lambda 3 and spontaneous recovery from HCV. Furthermore, we have identified HCV-specific CD8+ T cells within the maternal-fetal interface that we hypothesize demonstrate versatile functional attributes that prevent transmission in the majority of cases. We will also study how antigen-presenting cells in the decidua cross- present HCV antigens from trophoblasts and prime CD8+ T cells within the maternal fetal interface. Thus, our proposal seeks to mechanistically understand the different cells and signals that underpin HCV transmission versus protection.
摘要 丙型肝炎病毒(HCV)是美国最常见的血液传播感染,总体而言, 患病率约为2%,全世界估计有2亿慢性感染者。了大量的 证据,包括我们实验室的工作,支持这一概念,即早期事件的协调和 多细胞免疫应答的性质在确定病毒是否被清除或是否 持久性已经建立。然而,尽管每年大约有40 000例怀孕, 在HCV感染的妇女中,对HCV感染的免疫发病机制或保护性免疫的相关性知之甚少, 这种情况下,部分原因是孕妇与慢性丙型肝炎病毒迄今已被排除在研究 免疫力这是我们第一次提出证据,证明滋养层,胎盘的专门细胞, 在胚胎着床和与蜕膜化母体子宫的相互作用中起重要作用,可摄取HCV 蛋白质以及对丙型肝炎病毒产物(称为病原体相关分子)的反应 模式或PAMP)通过产生高水平的III型IFN。这些有趣的结果证实了最近 研究表明编码干扰素的单核苷酸多态性与遗传相关 λ 3和从HCV自发恢复。此外,我们还鉴定了HCV特异性CD 8 + T细胞, 在我们假设的母胎界面中, 在大多数情况下,传播。我们还将研究蜕膜中的抗原呈递细胞如何交叉- 从滋养层呈递HCV抗原,并在母胎界面内引发CD 8 + T细胞。因此,在本发明中, 我们的建议旨在从机制上理解支持HCV的不同细胞和信号 传输与保护。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARGARET G PETROFF其他文献

MARGARET G PETROFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARGARET G PETROFF', 18)}}的其他基金

Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
  • 批准号:
    10396646
  • 财政年份:
    2020
  • 资助金额:
    $ 33.6万
  • 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
  • 批准号:
    10215585
  • 财政年份:
    2020
  • 资助金额:
    $ 33.6万
  • 项目类别:
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
  • 批准号:
    10116259
  • 财政年份:
    2020
  • 资助金额:
    $ 33.6万
  • 项目类别:
Endocrine regulation of maternal immunity in pregnancy
孕期母体免疫力的内分泌调节
  • 批准号:
    9979498
  • 财政年份:
    2020
  • 资助金额:
    $ 33.6万
  • 项目类别:
Maternal Central Immune Tolerance in Reproduction
母体生殖中枢免疫耐受
  • 批准号:
    10617856
  • 财政年份:
    2020
  • 资助金额:
    $ 33.6万
  • 项目类别:
Shared Placenta/Tumor Antigens and Maternal Immunity
共享胎盘/肿瘤抗原和母体免疫
  • 批准号:
    9316903
  • 财政年份:
    2017
  • 资助金额:
    $ 33.6万
  • 项目类别:
INNATE AND ADAPTIVE IMMUNITY TO HCV IN HUMAN PREGNANCY
人类妊娠期对 HCV 的先天性和适应性免疫
  • 批准号:
    9021550
  • 财政年份:
    2014
  • 资助金额:
    $ 33.6万
  • 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
  • 批准号:
    8038448
  • 财政年份:
    2010
  • 资助金额:
    $ 33.6万
  • 项目类别:
Maternal Central Immune Tolerance to the Fetal-Placental Unit
母体对胎儿胎盘单位的中枢免疫耐受
  • 批准号:
    7774089
  • 财政年份:
    2010
  • 资助金额:
    $ 33.6万
  • 项目类别:
FUNCTIONAL COOPERATION BETWEEN TROPHOBLAST HLA-G AND B7 FAMILY
滋养层 HLA-G 和 B7 家族之间的功能合作
  • 批准号:
    7699715
  • 财政年份:
    2008
  • 资助金额:
    $ 33.6万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 33.6万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 33.6万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 33.6万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 33.6万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 33.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 33.6万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 33.6万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 33.6万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 33.6万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 33.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了